Inebilizumab
Inebilizumab (previously known as MEDI-551) is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. Inebilizumab is currently being tested in a phase 2 study for treating Neuromyelitis Optica Spectrum Disorder (NMOSD). NMOSD is a rare autoimmune disorder in which immune system cells and autoantibodies attack and damage the optic nerves and spinal cord. Clinically, the disease is manifested with attacks/relapses that result in neurological impairment such as blindness, paraplegia, sensory loss, bladder dysfunction, and peripheral pain. The disability from each attack is cumulative, making NMOSD a chronically debilitating and potentially life-threatening disease.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CD19 |
Clinical data | |
Other names | MEDI-551 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6504H10080N1732O2044S44 |
Molar mass | 146652.90 g·mol−1 |
References
- "Portfolio | Viela Bio". Viela Bio. Retrieved 2018-11-14.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.